MORGANTOWN — The state Department of Health and Human Resources Medicaid Fraud Control Unit announced Oct. 10 that it will receive more than $1.9 million in restitution and other recovery from a settlement agreement between the state and Mylan Inc. and its subsidiary, Mylan Specialty LP.

The settlement resolved allegations that Mylan made false statements to Medicaid by misclassifying its EpiPen product and lowered the amount of rebates the company was required to pay to Medicaid under federal law, DHHR said.

According to the unit, all 50 states have entered into agreements with Mylan following Mylan’s August announcement that it had signed an agreement with the U.S. Department of Justice finalizing the $465 million Medicaid drug rebate settlement that the company announced in October 2016.

The settlement, Mylan said in August, did not contain an admission or finding of wrongdoing. Mylan retroactively reclassified its EpiPen Auto-Injector for purposes of the Medicaid Drug Rebate Program as of April 1.